Skip to main content

Advertisement

SpringerLink
Log in

Influence on survival of p24 antigen levels in patients with AIDS or advanced AIDS related complex treated with zidovudine

  • Notes
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

In a prospective study sixty-eight patients consecutively diagnosed as having AIDS or advanced ARC who were started on zidovudine therapy were followed up for a median period of 725 days. In the 20 patients who had a baseline p24 antigen level above 20 pg/ml, there was a statistically significant trend towards reduction of the p24 antigen levels after the first month of treatment. The median time of survival of the 68 patients was 702 days and the median symptom-free period was 510 days. Treatment with zidovudine significantly reduced the p24 antigen levels. However, the life expectancy and the symptom-free period were not statistically different in the patients with p24 antigen levels always below or with levels always above two arbitrarily chosen cut-off points of 20 pg/ml and 50 pg/ml, respectively.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jackson GG, Paul DA, Falk LA, Rubenis M, Despostes JC, Mack D, Knigge M, Emeson EE: Human immunodeficiency virus antigenemia (p24) in the acquired immunodeficiency syndrome and the effect of treatment with zidovudine (AZT). Annals of Internal Medicine 1988, 108: 175–180.

    Google Scholar 

  2. Allain JP, Laurian Y, Paul DA, Verroust F, Leuther M, Gazengel C, Senn D, Larrieu MJ, Bosser C: Long term evaluation of HIV antigen and antibodies to p24 and gp41 in patients with hemophilia: potential clinical importance. New England Journal of Medicine 1987, 317: 1114–1121.

    Google Scholar 

  3. Pederson G, Nielsen CM, Vestergaard BF, Gerstoft J, Krogsaard K, Nielsen JO: Temporal relation of antigenaemia and loss of antibodies to core antigens to development of clinical disease in HIV infection. British Medical Journal 1987, 295: 567–589.

    Google Scholar 

  4. Forster SM, Osborne LM, Cheingsong-Popov R, Kenny C, Burnell R, Jeffries DJ, Pinching AJ, Harris JR, Weber JN: Decline of anti-p24 antibody precedes antigenaemia as a correlate of prognosis in HIV-1 infection. AIDS 1987, 1: 235–240.

    Google Scholar 

  5. MacDonell KB, Chmid JS, Poggensee L, Wu S, Phair JP: Predicting progression to AIDS: combined usefulness of CD4 lymphocyte counts and p24 antigenemia. American Journal of Medicine 1990, 89: 706–712.

    Google Scholar 

  6. Polis MA, Masur H: Predicting the progression to AIDS. American Journal of Medicine 1990, 89: 701–705.

    Google Scholar 

  7. Schechter MT, Craib KJP, Lee TN, Willoughby B, Douglas B, Sestak P, Montaner J, Weaver MS, Elmslie KD, O'Saughnessy MV: Progression to AIDS and predictors of AIDS in seroprevalent and seroincident cohorts of homosexual men. AIDS 1989, 3: 347–353.

    Google Scholar 

  8. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JC, Mildvan D, Schooley RT: The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind placebo-controlled trial. New England Journal of Medicine 1987, 317: 185–191.

    Google Scholar 

  9. Angarano G, Fiore JR, Casalino C, Monno L, Esposito M, Pastore G: Correlation between serum p24 antigen and the isolation of human immunodeficiency virus from the lymphocytes of subjects with HIV infection. Bolletin de la Societa Italiana de Biologia Sperimentale 1988, 64: 739–745.

    Google Scholar 

  10. Chaisson RE, Allain JP, Volderding PA: Significant changes in HIV antigen level in the serum of patients treated with azidothimidine. New England Journal of Medicine 1986, 315: 1610–1611.

    Google Scholar 

  11. Williams IG, Gabriel G, Kelly G, Loveday C, Tedder RS, Weller IVD: Response of serum p24 antigen and antibody to p24 antigen in patients with AIDS and AIDS-related complex treated with zidovudine. AIDS 1990, 4: 909–912.

    Google Scholar 

  12. Yarchoan R, Perno CF, Thomas RV, Klecker RW, Allain JP, Wills RJ, McAtee N, Fischl MA, Dubinsky R, McNeely MC, Mitsuya H, Pluda JM, Lawky TJ, Leuther M, Safai B, Collins JM, Myers CE, Broder S: Phase I studies of 2′,3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet 1988, i: 76–80.

    Google Scholar 

  13. Lambert JS, Seidlin M, Reichman RC, Plank CS, Laverty M, Morse GD, Knupp C, McLaren C, Pettinelli C, Valentine FT, Dolin R: 2′-3′-dideoxyionosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. New England Journal of Medicine 1990, 322: 1333–1340.

    Google Scholar 

  14. Cooley TP, Kunches LM, Saunders CA, Ritter JK, Perkins CJ, McLaren C, McCaffrey RP, Liebman HA: Once-daily administration of 2′-3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a phase I trial. New England Journal of Medicine 1990, 322: 1340–1345.

    Google Scholar 

  15. Mulder JW, Krijnen P, Goudsmit J, Schttenkerk JK, Reiss P, Lange JM: HIV-1 p24 antigenaemia does not predict time of survival in AIDS patients. Genitourinary Medicine 1990, 66: 138–141.

    Google Scholar 

  16. Centers for Disease Control: Revision of the case definition of acquired immune deficiency syndrome. Mortality and Morbidity Weekly Report 1987, 36: 1S–15S.

    Google Scholar 

  17. Armitage P: Statistical methods in medical research. Blackwell, Oxford, 1980.

    Google Scholar 

  18. Glantz SA: Primer of biostatistics. Mc-Graw-Hill, New York, 1987.

    Google Scholar 

  19. Cox DR: Regression models and life tables. Journal of the Royal Statistic Society of Britain 1977, 34: 187.

    Google Scholar 

  20. Falk LA, Paul D, Landay A, Kessler H: HIV isolation from plasma of HIV infected persons. New England Journal of Medicine 1987, 316: 1547–1548.

    Google Scholar 

  21. Coombs RW, Collier AC, Allain JP, Nikora B, Leuther M, Gjerset GF, Corey L: Plasma viremia in human immunodeficiency virus infection. New England Journal of Medicine 1989, 321: 1626–1631.

    Google Scholar 

  22. Ho DD, Moudgil T, Alam M: Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. New England Journal of Medicine 1989, 321: 1621–1625.

    Google Scholar 

  23. Gallo RC, Salahuddin SZ, Popovic M, Shearer GM, Kaplan M, Haynes BF, Palker TJ, Redfield R, Oleske J, Safai B, White G, Foster R, Markham PD: Frequent detection and isolation of cytopathic retroviruses (HTLV III) from patients with AIDS and at risk for AIDS. Science 1984, 224: 500–502.

    Google Scholar 

  24. Popovic M, Sarngadharan M, Read E, Gallo RC: Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984, 224: 497–500.

    Google Scholar 

  25. Bhalla RB: Abnormally high concentrations of beta 2 microglobulin in acquired immunodeficiency syndrome patients. Clinical Chemistry 1983, 29: 1560–1563.

    Google Scholar 

  26. Jacobson MA, Bacchetti P, Kolokathis A, Chaisson RE, Szabo S, Polsky B, Valainis GT, Mildvan D, Abrams D, Wilber J, Winger E, Sacks HS, Hendricksen C, Moss A: Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine. British Medical Journal 1991, 302: 73–78.

    Google Scholar 

  27. Dournon E, Matherson S, Rozenbaum W, Gharakhanian S, Michon C, Girard PM, Perrone C, Salmon D, De Truchis P, Leport C: Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex. Lancet 1988, ii: 1297–1302.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Infectious Disease Unit, University Hospital, Faculty of Medicine, Villarroel 170, 08036, Barcelona, Spain

    L. Zamora, J. M. Gatell, E. Buira, J. M. Miro & E. Soriano

  2. Hematological Laboratory, University Hospital, Faculty of Medicine, Villarroel 170, 08036, Barcelona, Spain

    J. M. Barrera, G. Ercilla & C. Gil

Authors
  1. L. Zamora
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. M. Gatell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. M. Barrera
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Ercilla
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Gil
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. Buira
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. M. Miro
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. E. Soriano
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zamora, L., Gatell, J.M., Barrera, J.M. et al. Influence on survival of p24 antigen levels in patients with AIDS or advanced AIDS related complex treated with zidovudine. Eur. J. Clin. Microbiol. Infect. Dis. 11, 1181–1185 (1992). https://doi.org/10.1007/BF01961142

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01961142

Keywords

Search

Navigation